Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Acute Myocardial Infarction Condition: Accelerated infusion (1.5 hours) |
Dose: Intravenous – 15 mg intravenous push bolus over 1-2 minutes, then 0.75 mg/kg intravenous infusion over 30 minutes (not to exceed 50 mg), then 0.5 mg/kg intravenous over next 60 minutes (not to exceed 35 mg over 1 hour) Note: Administer as soon as possible after onset of symptoms; Recommended total dose is based on patient weight, not to exceed 100 mg |
|
Indication: Acute Myocardial Infarction Condition: Accelerated infusion (1.5 hours) |
Dose: Intravenous – 15 mg intravenous push bolus over 1-2 minutes, then 50 mg intravenous infusion over next 30 minutes, then remaining 35 mg over next 60 minutes Note: Administer as soon as possible after onset of symptoms; Total dose 100 mg infused over 1.5 hours |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Central Venous Catheter Occlusion |
Dose: Instill – 110% of the internal lumen volume of the catheter Note: not to exceed 2 mg in 2 mL; Assess catheter function after 30 minutes of dwell time by attempting to aspirate blood; if unable to aspirate after 120 minutes dwell time, a second dose may be administered and the process repeated; If catheter function restored, aspirate 3 mL blood to remove injection solution and residual clot; Gently irrigate with 0.9% Sodium Chloride |
|
Indication: Central Venous Catheter Occlusion |
Dose: Instill – 2 mg Note: instilled into occluded catheter; Assess catheter function after 30 minutes of dwell time by attempting to aspirate blood; if unable to aspirate after 120 minutes dwell time, a second dose may be administered and the process repeated; If catheter function restored, aspirate 4-5 mL blood to remove injection solution and residual clot; Gently irrigate with 0.9% Sodium Chloride |
Administration
- Given as intravenous infusion
- Must be administered by healthcare professionals
Side Effect
- Stroke (1.6%)
- Accelerated idioventricular rhythm
- Pulmonary edema
- Arterial embolism
- Bruising
- Bleeding
- DVT
- Hypotension
- Intracranial hemorrhage
- GI/GU hemorrhage
- Pulmonary embolism
- Fever/chills
- Nausea/vomiting
- Sensitivity reaction
- Sepsis
- Shock
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
GPIIb/IIIa antagonists
|
Increased risk of bleeding
|
|
Coumarine derivatives, oral Anticoagulants (Warfarin, Heparin, Dabigatran, Rivaroxaban, Apixaban, Edoxaban), platelet aggregation inhibitors, unfractionated heparin, LMWH
|
Increased risk of haemorrhage
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
Current Intracranial Hemorrhage
|
Risk of fatal bleeding
|
|
Recent Brain/Spine Surgery
|
Risk of surgical site bleeding
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Store lyophilized Alteplase at controlled room temperature not to exceed 30°C, or under refrigeration (2-8°C). Protect the lyophilized material during extended storage from excessive exposure to light. If stored between 2-30°C, Alteplase may be used within 8 hours following reconstitution. Discard any unused solution after administration is complete. Do not use beyond the expiration date stamped on the vial.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.